Treatment of a genetically diverse set of NSCLC lines with valproate reduced the expression of PD-L1, PD-L2 and ODC, and increased the expression of MHCA and HMGB1 (Supplementary Figure 17B). This evidence concerns the gene CD274 and non-small cell lung carcinoma.